Navigation Links
Children's Memorial Hospital, Chicago, joins ExCell study
Date:1/7/2009

Chicago, Illinois and Jerusalem, Israel, January 7, 2009 --- Children's Memorial Hospital and the Gamida Cell - Teva Joint Venture (JV) announced today that Children's Memorial has joined a select group of cancer centers in Europe, the United States and Israel, actively enrolling patients for the ExCell study. The pivotal registration study is testing the safety and efficacy of StemEx, a potential alternative transplantation option for adolescents and adults with leukemia, lymphoma and other high-risk hematological malignancies, who are unable to find an adequately matched, bone marrow donor. StemEx is being developed by a Joint Venture equally owned and managed by Jerusalem-based biomedical company Gamida Cell and Teva Pharmaceutical Industries (NASDAQ: TEVA).

For many patients suffering from blood-based cancers such as leukemia and lymphoma, the odds of survival have been historically poor because they cannot find a suitable match bone marrow donor. According to the National Marrow Donor Program, each year in the United States more than 70 percent of the 35,000 patients with life-threatening diseases who could benefit from a bone marrow transplant cannot be matched with a donor.

"We are hopeful that this unique cellular technology will benefit our transplant patients at Children's Memorial. We also believe that this new methodology may expand the role for stem cell transplantation in treating life-threatening diseases, especially in patients without matched donors." said lead investigator Sonali Chaudhury, MD, attending physician in the Division of Hematology, Oncology and Stem Cell Transplantation at Children's Memorial and assistant professor of pediatrics at Northwestern University's Feinberg School of Medicine.

Research shows that cells derived from umbilical cord blood (UCB) can effectively be used for bone marrow transplantation. In addition, cord blood transplants have been associated with a reduced risk for Graft versus Host Disease (GvHD). StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non-expanded cells from the same unit. While UCB has been used mainly for the treatment of small children, the increase in stem/progenitor cells through StemEx, boosts the therapeutic potential of this treatment for adolescents and adults. The preliminary results of the Phase I/II study of StemEx presented at the 2004 Annual Meeting of the American Society of Hematology (ASH) in San Diego California, encouraged the further investigation of the safety and efficacy of StemEx in the ExCell study.

"We are proud to work together with Dr. Chaudhury in an effort to improve care for adolescents being treated at Children's Memorial," said Dr. David Snyder, vice president of clinical development at Gamida Cell.


'/>"/>

Contact: Julie Pesch
jpesch@childrensmemorial.org
773-880-3055
Children's Memorial Hospital
Source:Eurekalert

Related medicine news :

1. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
2. Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash
3. Siegel+Gale Designs New HOPE Portal for Childrens Hospital Los Angeles
4. Jessica Biel and Make The Difference Network Bring Holiday Cheer to Childrens Hospital Los Angeles
5. Childrens Memorial Hospital in Chicago Announces $100 Million Gift from Philanthropist Ann Lurie
6. Physician Team at Northwestern Memorial Performs Rare Oral Gallbladder Removal
7. WaveMark, Inc. is Chosen by UMass Memorial Medical Center
8. Chubby Checker Adds Twist to 10,000 Strong at Ninth Annual Walk to Cure Cancer for UMass Memorial Cancer Center at the UMass Medical School
9. American Diabetes Association Announces Three Year Collaboration With The Dignity Memorial(R) Network
10. Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery
11. Baptist Memorial Health Care Donates More Than $3 Million to Tennessee Universities and Colleges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA Senior ... not obey the rules Congress has directed the CBO to follow. The CBO itself ... would restore. Yet, it estimates a reduction in employer-based coverage due to the GOP ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . ... for the product – with nearly 2,000 consumers (and counting) already backing the ...
(Date:3/24/2017)... ... ... who like to educate themselves on current issues and who enjoy gaining knowledge on ... to appreciate and love the "Informed" series, hosted by Rob Lowe. A new ... the world. , Running for charity has become a multi-million dollar enterprise ...
(Date:3/24/2017)... ... 2017 , ... “End Time GPS”: a dauntless and enlightened study of ... GPS” is the creation of published author, Wesley Gerboth, a World War II veteran, ... space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him ...
(Date:3/23/2017)... ... , ... A recent report from the National Council on Teacher Quality (NCTQ) ... suggests, based on a review of GPA and SAT/ACT requirements at 221 institutions in ... It argues that this higher bar should be set by states, by the Council ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets has ... Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a total ... & Co., Inc., Biogen and Sanofi are involved in the development of ... which one is in Phase III stage, 15 are in Phase II ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , Latin ... provided for the period 2015 through 2022. Also, a six-year historic analysis ...
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... Financing Commitment Term Sheet (the "Definitive Financing") it ... of the Company,s stockholders, who are referred to ... a Form 8-K filed with the Securities and ...
Breaking Medicine Technology: